IBI363 before surgery for stage II-III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests an experimental drug called IBI363 given before surgery for people with stage II to III non-small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer (NSCLC) that can be surgically removed (stages II, IIIA, or IIIB with N2).
- You have not received any prior treatment for this lung cancer before surgery.
- Your lung cancer does not have an EGFR mutation or an ALK gene change.
- Your tumor tests positive for PD-L1 (a protein that helps cancer hide) at a TPS level of 1% or higher.
- You are able to care for yourself (ECOG score 0 or 1) and your lungs are healthy enough for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests a new drug called IBI363 for people with extensive-stage small cell lung cancer whose cancer has continued to grow after immunotherapy and other treatments. It aims to see if IBI363 can help shrink tumors or slow the disease.
Hear when a new Resectable Stage II-III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.